Rocconi RP, Monk BJ, Walter A, Herzog TJ, et al. Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680]. Gynecol Oncol 2022 Nov 28:S0090-8258(22)01924.
PMID: 36456375